Estrella Immunopharma, Inc. (ESLA)

Estrella Immunopharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Mar 31, 2026	Dec 31, 2025	Jun 30, 2024	Jun 30, 2023
Selling, General & Admin	3.01	2.81	3.2	0.66
Research & Development	10.24	10.25	4.11	10.45
Total Operating Expenses	13.25	13.06	7.31	11.11
Operating Income	-13.25	-13.06	-7.31	-11.11
Pretax Income	-13.25	-13.06	-7.31	-11.11
Provision for Income Taxes	0	0	0	-
Net Income	-13.25	-13.06	-7.31	-11.11
Net Income to Common	-13.25	-13.06	-7.31	-11.11
Shares Outstanding (Basic)	38	37	27	1
Shares Outstanding (Diluted)	38	37	27	1
Shares Change (YoY)	6.92%	35.85%	1809.14%	-
EPS (Basic)	-0.34	-0.35	-0.27	-36.35
EPS (Diluted)	-0.34	-0.35	-0.27	-36.35
Shares Outstanding	42.67	37.97	36.29	3.75
Free Cash Flow	-	-1.79	-16.07	-1.34
Free Cash Flow Per Share	-	-0.05	-0.59	-0.94
EBITDA	-13.25	-13.06	-7.31	-11.11
EBIT	-13.25	-13.06	-7.31	-11.11
Effective Tax Rate	-0.01%	-0.01%	-0.02%	0.00%

Updated May 16, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q